Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026)
Viking Therapeutics (VKTX) reported Income from Continuing Operations of 266375000.0 for Q1 2026, down 119.6% on a YoY basis from 1358793672.99 in Q1 2025, and up 4.44% sequentially from 278748000.0 in Q4 2025.
Viking Therapeutics (VKTX) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of Income from Continuing Operations data on file, last reported at 266375000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 119.6% year-over-year to 266375000.0; the trailing twelve-month figure through Mar 2026 stood at 869294000.0 (down 1.47% YoY), and the FY2025 full-year result was 506223000.0, down 60.63% from the prior year.
- Income from Continuing Operations grew to 266375000.0 in Q1 2026, from 278748000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 17848000.0 in Q3 2022 to a low of 60347036000.0 in Q1 2023.
- A 5-year average of 7980763743.59 and a median of 189787000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations slumped 318707.31% in 2023 and jumped 99.48% in 2024, its largest moves.
- Tracing VKTX's Income from Continuing Operations over 5 years: stood at 40280000.0 in 2022, then plunged by 126.06% to 91058000.0 in 2023, then sank by 108.42% to 189787000.0 in 2024, then slumped by 46.87% to 278748000.0 in 2025, then advanced by 4.44% to 266375000.0 in 2026.
- Business Quant data shows VKTX's Income from Continuing Operations at 266375000.0 in Q1 2026, 278748000.0 in Q4 2025, and 173016000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Viking Therapeutics | 4.03 Bn | 4.03 Bn | - | -266.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -266.38 Mn |
| Dec 31, 2025 | -278.75 Mn |
| Sep 30, 2025 | -173.02 Mn |
| Jun 30, 2025 | -151.16 Mn |
| Mar 31, 2025 | -121.30 Mn |
| Dec 31, 2024 | -189.79 Mn |
| Sep 30, 2024 | -288.03 Mn |
| Jun 30, 2024 | -257.58 Mn |
| Mar 31, 2024 | -436.20 Mn |
| Dec 31, 2023 | -91.06 Mn |
| Sep 30, 2023 | -23.36 Bn |
| Jun 30, 2023 | -49.62 Bn |
| Mar 31, 2023 | -60.35 Bn |
| Dec 31, 2022 | -40.28 Mn |
| Sep 30, 2022 | -17.85 Mn |
| Jun 30, 2022 | -19.45 Mn |
| Mar 31, 2022 | -18.93 Mn |
| Dec 31, 2021 | -15.77 Mn |
| Sep 30, 2021 | -18.95 Mn |
| Jun 30, 2021 | -20.59 Mn |